LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 7 of total 7

Search options

  1. Article: Food-specific IgG Antibody-guided Elimination Diets Followed by Resolution of Asthma Symptoms and Reduction in Pharmacological Interventions in Two Patients: A Case Report.

    Virdee, Kulveen / Musset, Jeannette / Baral, Matthew / Cronin, Courtney / Langland, Jeffrey

    Global advances in health and medicine

    2015  Volume 4, Issue 1, Page(s) 62–66

    Abstract: Asthma is one of the most common causes of office visits in the primary care and emergency care settings. Individuals are often able to maintain symptomatic control with long-term pharmacological therapy. Exacerbations of asthma commonly occur due to ... ...

    Abstract Asthma is one of the most common causes of office visits in the primary care and emergency care settings. Individuals are often able to maintain symptomatic control with long-term pharmacological therapy. Exacerbations of asthma commonly occur due to exposure to triggers such as viruses, pollutants, and allergens. While it is widely accepted that exposure to immunoglobulin E food allergens can exacerbate asthma symptoms, there is little evidence examining delayed immunoglobulin G-mediated reactions to food. Here we present two clinical cases of individuals who experienced a reduction in asthma symptoms, decreased dependence on pharmacological therapies, and increased quality of life by eliminating foods that demonstrated reactivity to immunoglobulin G levels identified through serum testing.
    Language English
    Publishing date 2015-02-10
    Publishing country United States
    Document type Case Reports
    ZDB-ID 2709002-4
    ISSN 2164-9561 ; 2164-957X
    ISSN (online) 2164-9561
    ISSN 2164-957X
    DOI 10.7453/gahmj.2014.068
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article: Biomarker-guided interventions of clinically relevant conditions associated with autism spectrum disorders and attention deficit hyperactivity disorder.

    Bradstreet, James Jeffrey / Smith, Scott / Baral, Matthew / Rossignol, Daniel A

    Alternative medicine review : a journal of clinical therapeutic

    2010  Volume 15, Issue 1, Page(s) 15–32

    Abstract: Autism spectrum disorders (ASD) and attention-deficit hyperactivity disorder (ADHD) are common and complex neurodevelopmental conditions. Diagnostic criteria for these conditions have traditionally relied solely on behavioral criteria without ... ...

    Abstract Autism spectrum disorders (ASD) and attention-deficit hyperactivity disorder (ADHD) are common and complex neurodevelopmental conditions. Diagnostic criteria for these conditions have traditionally relied solely on behavioral criteria without consideration for potential biomedical underpinnings. Newer evidence, however, reveals that ASDs are associated with: oxidative stress; decreased methylation capacity; limited production of glutathione; mitochondrial dysfunction; intestinal dysbiosis; increased toxic metal burden; immune dysregulation, characterized by a unique inflammatory bowel disease and immune activation of neuroglial cells; and ongoing brain hypoperfusion. Many of these same problems are common features in children with ADHD. These medical conditions, whether co-morbidities or etiopathogenic, would be expected to have synergistically negative effects on the development, cognition, focus, and attention of affected children. It is likely these biological abnormalities contribute significantly to the behavioral symptoms intrinsic in these diagnoses. However, treatment for these underlying medical disorders is clinically justified, even if no clear immediate behavioral improvements are observed. This article reviews the medical literature and discusses the authors clinical experience using various biomarkers for measuring oxidative stress, methylation capacity and transsulfuration, immune function, gastrointestinal problems, and toxic metal burden. These biomarkers provide useful guides for selection, efficacy, and sufficiency of biomedical interventions. The use of these biomarkers is of great importance in young children with ADHD or individuals of any age with ASD, because typically they cannot adequately communicate regarding their symptoms.
    MeSH term(s) Attention Deficit Disorder with Hyperactivity/complications ; Attention Deficit Disorder with Hyperactivity/etiology ; Attention Deficit Disorder with Hyperactivity/metabolism ; Biomarkers/metabolism ; Child ; Child Development Disorders, Pervasive/complications ; Child Development Disorders, Pervasive/etiology ; Child Development Disorders, Pervasive/metabolism ; Child Development Disorders, Pervasive/prevention & control ; Environmental Pollutants/toxicity ; Female ; Humans ; Inflammation/complications ; Inflammation/metabolism ; Intestinal Diseases/complications ; Male ; Metals, Heavy/toxicity ; Mitochondrial Diseases/complications ; Oxidative Stress
    Chemical Substances Biomarkers ; Environmental Pollutants ; Metals, Heavy
    Language English
    Publishing date 2010-04
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 1465535-4
    ISSN 1089-5159
    ISSN 1089-5159
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4997: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Safety and efficacy of oral DMSA therapy for children with autism spectrum disorders

    Gehn Eva / Newmark Sanford / Zappia Irene / Hensley Andrea / Ingram Julie / Mitchell Jessica / Geis Elizabeth / Baral Matthew / Adams James B / Rubin Robert A / Mitchell Ken / Bradstreet Jeff / El-Dahr Jane

    BMC Clinical Pharmacology, Vol 9, Iss 1, p

    Part B - Behavioral results

    2009  Volume 17

    Abstract: Abstract Background This study investigated the effects of oral dimercapto succinic acid (DMSA) therapy on the behavioural symptoms of children with autism spectrum disorders (ASD) ages 3-8 years. Methods Phase 1 involved 65 children with ASD who ... ...

    Abstract Abstract Background This study investigated the effects of oral dimercapto succinic acid (DMSA) therapy on the behavioural symptoms of children with autism spectrum disorders (ASD) ages 3-8 years. Methods Phase 1 involved 65 children with ASD who received one round of DMSA (3 days). Participants who had high urinary excretion of toxic metals were selected to continue on to phase 2. In phase 2, 49 participants were randomly assigned in a double-blind design to receive an additional 6 rounds of either DMSA or placebo. Results The groups receiving one round and seven rounds of DMSA had significant improvements on all the assessment measures. For the seven round group, the degree of improvement on the assessment measures could be partially explained by a regression analysis based on excretion of toxic metals and changes in glutathione (adjusted R 2 of 0.28-0.75, p < 0.02 in all cases). One round of DMSA had nearly the same benefit as seven rounds. The assessment measures correlated reasonably with one another at the beginning of the study (r = 0.60-0.87) and even better at the end of the study (r = 0.63-0.94). Conclusion Overall, both one and seven rounds of DMSA therapy seems to be reasonably safe in children with ASD who have high urinary excretion of toxic metals, and possibly helpful in reducing some of the symptoms of autism in those children.
    Keywords Therapeutics. Pharmacology ; RM1-950 ; Medicine ; R ; DOAJ:Therapeutics ; DOAJ:Medicine (General) ; DOAJ:Health Sciences
    Subject code 150
    Language English
    Publishing date 2009-10-01T00:00:00Z
    Publisher BioMed Central
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  4. Article ; Online: Safety and efficacy of oral DMSA therapy for children with autism spectrum disorders

    Gehn Eva / Newmark Sanford / Zappia Irene / Hensley Andrea / Ingram Julie / Mitchell Jessica / Geis Elizabeth / Baral Matthew / Adams James B / Rubin Robert A / Mitchell Ken / Bradstreet Jeff / El-Dahr Jane

    BMC Clinical Pharmacology, Vol 9, Iss 1, p

    Part A - Medical results

    2009  Volume 16

    Abstract: Abstract Background This study investigated the effect of oral dimercapto succinic acid (DMSA) therapy for children with autism spectrum disorders ages 3-8 years. Methods Phase 1 involved 65 children who received one round of DMSA (3 days). Participants ... ...

    Abstract Abstract Background This study investigated the effect of oral dimercapto succinic acid (DMSA) therapy for children with autism spectrum disorders ages 3-8 years. Methods Phase 1 involved 65 children who received one round of DMSA (3 days). Participants who had high urinary excretion of toxic metals were selected to continue on to phase 2. In phase 2, 49 participants were randomly assigned in a double-blind design to receive an additional 6 rounds of either DMSA or placebo. Results DMSA greatly increased the excretion of lead, substantially increased excretion of tin and bismuth, and somewhat increased the excretion of thallium, mercury, antimony, and tungsten. There was some increase in urinary excretion of essential minerals, especially potassium and chromium. The Phase 1 single round of DMSA led to a dramatic normalization of RBC glutathione in almost all cases, and greatly improved abnormal platelet counts, suggesting a significant decrease in inflammation. Conclusion Overall, DMSA therapy seems to be reasonably safe, effective in removing several toxic metals (especially lead), dramatically effective in normalizing RBC glutathione, and effective in normalizing platelet counts. Only 1 round (3 days) was sufficient to improve glutathione and platelets. Additional rounds increased excretion of toxic metals.
    Keywords Therapeutics. Pharmacology ; RM1-950 ; Medicine ; R ; DOAJ:Therapeutics ; DOAJ:Medicine (General) ; DOAJ:Health Sciences
    Language English
    Publishing date 2009-10-01T00:00:00Z
    Publisher BioMed Central
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  5. Article: Efficacy of probiotics and nutrients in functional gastrointestinal disorders: a preliminary clinical trial.

    S Kim, Linda / Hilli, Lisa / Orlowski, Jennifer / Kupperman, Jami L / Baral, Matthew / F Waters, Robert

    Digestive diseases and sciences

    2006  Volume 51, Issue 12, Page(s) 2134–2144

    Abstract: The purpose of this study was to evaluate the efficacy and safety of commonly used probiotics and nutrients available for functional gastrointestinal disorders (FGID). Five different combinations of probiotics and nutrients, or placebo, were taken daily ... ...

    Abstract The purpose of this study was to evaluate the efficacy and safety of commonly used probiotics and nutrients available for functional gastrointestinal disorders (FGID). Five different combinations of probiotics and nutrients, or placebo, were taken daily over 12 weeks. In this randomized controlled clinical trial, men and women 21 to 72 years of age with FGID symptoms of indigestion, bloating, and abdominal discomfort were assigned to one of six groups, 12 patients per group. Gastrointestinal Quality of Life Index (GIQLI) and visual analogue scale (VAS) for GI symptoms, SF-36, lactulose and mannitol test (LMT), and urine indican levels were evaluated. GIQLI, VAS scores, and LMT did not change significantly (P > 0.05). There were clinically notable improvements in two of the combination formulations. While the nonsignificant improvements in GI symptoms could suggest that combination probiotics and nutrients may be beneficial in conditions such as FGID, no conclusive evidence was found in this pilot trial. Further investigations to explore the findings are discussed.
    MeSH term(s) Abdominal Pain/drug therapy ; Abdominal Pain/physiopathology ; Adult ; Aged ; Dietary Supplements ; Double-Blind Method ; Dyspepsia/drug therapy ; Dyspepsia/physiopathology ; Female ; Gastrointestinal Diseases/complications ; Gastrointestinal Diseases/drug therapy ; Gastrointestinal Diseases/physiopathology ; Humans ; Indican/urine ; Male ; Middle Aged ; Pain Measurement ; Pilot Projects ; Plant Extracts/therapeutic use ; Probiotics/adverse effects ; Probiotics/therapeutic use ; Quality of Life
    Chemical Substances Plant Extracts ; Indican (N187WK1Y1J)
    Language English
    Publishing date 2006-11-01
    Publishing country United States
    Document type Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
    ZDB-ID 304250-9
    ISSN 1573-2568 ; 0163-2116
    ISSN (online) 1573-2568
    ISSN 0163-2116
    DOI 10.1007/s10620-006-9297-8
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ui V Zs.35: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Safety and efficacy of oral DMSA therapy for children with autism spectrum disorders: part B - behavioral results.

    Adams, James B / Baral, Matthew / Geis, Elizabeth / Mitchell, Jessica / Ingram, Julie / Hensley, Andrea / Zappia, Irene / Newmark, Sanford / Gehn, Eva / Rubin, Robert A / Mitchell, Ken / Bradstreet, Jeff / El-Dahr, Jane

    BMC clinical pharmacology

    2009  Volume 9, Page(s) 17

    Abstract: Background: This study investigated the effects of oral dimercapto succinic acid (DMSA) therapy on the behavioural symptoms of children with autism spectrum disorders (ASD) ages 3-8 years.: Methods: Phase 1 involved 65 children with ASD who received ... ...

    Abstract Background: This study investigated the effects of oral dimercapto succinic acid (DMSA) therapy on the behavioural symptoms of children with autism spectrum disorders (ASD) ages 3-8 years.
    Methods: Phase 1 involved 65 children with ASD who received one round of DMSA (3 days). Participants who had high urinary excretion of toxic metals were selected to continue on to phase 2. In phase 2, 49 participants were randomly assigned in a double-blind design to receive an additional 6 rounds of either DMSA or placebo.
    Results: The groups receiving one round and seven rounds of DMSA had significant improvements on all the assessment measures. For the seven round group, the degree of improvement on the assessment measures could be partially explained by a regression analysis based on excretion of toxic metals and changes in glutathione (adjusted R2 of 0.28-0.75, p < 0.02 in all cases). One round of DMSA had nearly the same benefit as seven rounds. The assessment measures correlated reasonably with one another at the beginning of the study (r = 0.60-0.87) and even better at the end of the study (r = 0.63-0.94).
    Conclusion: Overall, both one and seven rounds of DMSA therapy seems to be reasonably safe in children with ASD who have high urinary excretion of toxic metals, and possibly helpful in reducing some of the symptoms of autism in those children.
    MeSH term(s) Adaptation, Psychological/drug effects ; Aging ; Autistic Disorder/classification ; Autistic Disorder/complications ; Autistic Disorder/drug therapy ; Chelating Agents/adverse effects ; Chelating Agents/therapeutic use ; Child ; Child Behavior/drug effects ; Child, Preschool ; Drug Administration Schedule ; Glutathione/blood ; Heavy Metal Poisoning, Nervous System/complications ; Humans ; Metals, Heavy/toxicity ; Metals, Heavy/urine ; Parents/psychology ; Psychiatric Status Rating Scales ; Regression Analysis ; Succimer/adverse effects ; Succimer/therapeutic use ; Surveys and Questionnaires ; Treatment Outcome
    Chemical Substances Chelating Agents ; Metals, Heavy ; Succimer (DX1U2629QE) ; Glutathione (GAN16C9B8O)
    Language English
    Publishing date 2009-10-23
    Publishing country England
    Document type Clinical Trial ; Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
    ZDB-ID 2041488-2
    ISSN 1472-6904 ; 1472-6904
    ISSN (online) 1472-6904
    ISSN 1472-6904
    DOI 10.1186/1472-6904-9-17
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Safety and efficacy of oral DMSA therapy for children with autism spectrum disorders: Part A--medical results.

    Adams, James B / Baral, Matthew / Geis, Elizabeth / Mitchell, Jessica / Ingram, Julie / Hensley, Andrea / Zappia, Irene / Newmark, Sanford / Gehn, Eva / Rubin, Robert A / Mitchell, Ken / Bradstreet, Jeff / El-Dahr, Jane

    BMC clinical pharmacology

    2009  Volume 9, Page(s) 16

    Abstract: Background: This study investigated the effect of oral dimercapto succinic acid (DMSA) therapy for children with autism spectrum disorders ages 3-8 years.: Methods: Phase 1 involved 65 children who received one round of DMSA (3 days). Participants ... ...

    Abstract Background: This study investigated the effect of oral dimercapto succinic acid (DMSA) therapy for children with autism spectrum disorders ages 3-8 years.
    Methods: Phase 1 involved 65 children who received one round of DMSA (3 days). Participants who had high urinary excretion of toxic metals were selected to continue on to phase 2. In phase 2, 49 participants were randomly assigned in a double-blind design to receive an additional 6 rounds of either DMSA or placebo.
    Results: DMSA greatly increased the excretion of lead, substantially increased excretion of tin and bismuth, and somewhat increased the excretion of thallium, mercury, antimony, and tungsten. There was some increase in urinary excretion of essential minerals, especially potassium and chromium. The Phase 1 single round of DMSA led to a dramatic normalization of RBC glutathione in almost all cases, and greatly improved abnormal platelet counts, suggesting a significant decrease in inflammation.
    Conclusion: Overall, DMSA therapy seems to be reasonably safe, effective in removing several toxic metals (especially lead), dramatically effective in normalizing RBC glutathione, and effective in normalizing platelet counts. Only 1 round (3 days) was sufficient to improve glutathione and platelets. Additional rounds increased excretion of toxic metals.
    MeSH term(s) Administration, Oral ; Autistic Disorder/blood ; Autistic Disorder/drug therapy ; Autistic Disorder/urine ; Blood Cell Count/methods ; Child ; Child, Preschool ; Double-Blind Method ; Female ; Glutathione/blood ; Glutathione/urine ; Humans ; Male ; Metals/blood ; Metals/urine ; Succimer/administration & dosage ; Succimer/adverse effects ; Treatment Outcome
    Chemical Substances Metals ; Succimer (DX1U2629QE) ; Glutathione (GAN16C9B8O)
    Language English
    Publishing date 2009-10-23
    Publishing country England
    Document type Clinical Trial, Phase I ; Clinical Trial, Phase II ; Comparative Study ; Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
    ZDB-ID 2041488-2
    ISSN 1472-6904 ; 1472-6904
    ISSN (online) 1472-6904
    ISSN 1472-6904
    DOI 10.1186/1472-6904-9-16
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top